Skip to main content

Latest

inside the market
The former Valeant exits Canada’s big-stock index; energy stock added
The electronic ticker display outside the Toronto Stock Exchange Tower in Toronto, is photographed after the market closed on Monday, Jan., 24, 2022. (Christopher Katsarov/The Globe and Mail)
report on business
Bausch Health reports $145-million loss in the second quarter, lowers guidance
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. Bausch Health Companies Inc. says hedge fund manager John Paulson has been named chairperson of its board of directors, replacing Joseph Papa. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health shares plummet on adverse drug patent ruling
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. Bausch Health Companies Inc. says hedge fund manager John Paulson has been named chairperson of its board of directors, replacing Joseph Papa. THE CANADIAN PRESS/Ryan Remiorz
u.s. business
Bausch Health suspends plans for Solta IPO
CHICAGO, ILLINOIS - MAY 05: Bausch + Lomb eye vitamins are offered for sale at a drug store on May 05, 2022 in Chicago, Illinois. Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”. (Photo by Scott Olson/Getty Images)
report on business
Bausch Health reports US$69-million first-quarter loss, revenue down from year ago
The headquarters of Bausch Health Solutions is seen Wednesday, February 20, 2019 in Laval, Que.THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health selling stake in Egypt’s Amoun for $740-million
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. Bausch Health Companies Inc. had a smaller net loss and improved adjusted earnings in the second quarter and says it now expects 2019 revenue and adjusted earnings will be higher than the previous estimate. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health names Sam Eldessouky as next CFO
Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US$52 million. Bausch Health Companies Inc. is darkening its earnings forecast for the year after losing cash in the first quarter due to the COVID-19 pandemic. THE CANADIAN PRESS/Ryan Remiorz
u.s. business
Bausch Health to add two directors from Icahn Group to board
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., on February 20, 2019. THE CANADIAN PRESS/Ryan Remiorz
inside the market
Market movers: Stocks that saw action on Friday - and why
Pipelines run to Enbridge Inc.'s crude oil storage tanks at their tank farm in Cushing, Oklahoma, March 24, 2016.
report on business
Bausch Health shareholder pushes for completion of eye-care spinoff by end of 2021
Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US$52 million. Bausch Health Companies Inc. is darkening its earnings forecast for the year after losing cash in the first quarter due to the COVID-19 pandemic. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health expects 2020 revenue to exceed previous guidance
Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US$52 million. Bausch Health Companies Inc. is darkening its earnings forecast for the year after losing cash in the first quarter due to the COVID-19 pandemic. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health says COVID-19 cut third-quarter revenue by $150-million
Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US$52 million. Bausch Health Companies Inc. is darkening its earnings forecast for the year after losing cash in the first quarter due to the COVID-19 pandemic. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health to spin-off eye care business, shares soar 28%
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen Wednesday, February 20, 2019 in Laval, Que. Bausch Health Companies Inc. says it is ending significant legal matters from the Valeant era by agreeing to pay $94 million plus administration costs to resolve a Canadian securities class action. THE CANADIAN PRESS/Ryan Remiorz
streetwise newsletter
Streetwise newsletter: Manulife joint venture in China faced whistle-blower complaints
W5W0C0 --FILE--Passengers walk past an advertisement for Sino-Canadian joint-venture insurer Manulife-Sinochem Life Insurance Co Ltd at a metro station in Shanghai.
report on business
Years after Valeant scandal, SEC unveils charges against firm, former executives
The head office and logo of Valeant Pharmaceuticals are pictured in Montreal on May 27, 2013.
report on business
Bausch Health reports $152-million first-quarter loss due to COVID-19
Bausch Health Companies Inc. raised its guidance as it reported a first-quarter loss of US$52 million. Bausch Health Companies Inc. is darkening its earnings forecast for the year after losing cash in the first quarter due to the COVID-19 pandemic. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health CEO’s 2019 pay climbs to US$17.14-million
Valeant Pharmaceuticals International Inc's new chief executive Joseph Papa speaks to the press following their annual general meeting in Laval, Que., June 14, 2016.
inside the market
Market movers: Stocks that saw action on Wednesday - and why
Excavation is done in a new tunnel at Nutrien's Cory potash mine near Saskatoon.
report on business
Bausch Health reports $1.52-billion fourth-quarter loss due to stock drop lawsuit settlement
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., on February 20, 2019. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health agrees to pay US$1.21-billion to settle shareholder lawsuit
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen Wednesday, February 20, 2019 in Laval, Que.
report on business
Bausch Health settles share-price class action for $1.21-billion
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. Bausch Health Companies Inc. had a smaller net loss and improved adjusted earnings in the second quarter and says it now expects 2019 revenue and adjusted earnings will be higher than the previous estimate. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health raises full-year profit expectations
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., Wednesday, February 20, 2019. Bausch Health Companies Inc. had a smaller net loss and improved adjusted earnings in the second quarter and says it now expects 2019 revenue and adjusted earnings will be higher than the previous estimate. THE CANADIAN PRESS/Ryan Remiorz
report on business
Bausch Health reports first-quarter loss, raises full-year financial guidance
The headquarters of Bausch Health Solutions, formerly known as Valeant Inc., is seen in Laval, Que., on Feb. 20, 2019.
report on business
Bausch Health aims to balance debt-reduction, acquisitions and boost R&D in 2019
Valeant Pharmaceuticals International Inc's new chief executive Joseph Papa speaks to the press following their annual general meeting in Laval, Que., June 14, 2016.
report on business
Bausch Health forecasts increased revenue as it reduces heavy debt load
Joseph Papa, chief executive of Bausch Health, speaks to the press in Laval, Que., on June 14, 2016.
report on business
Bausch Health reports third-quarter loss, revenue edges lower
The head office and logo of Valeant Pharmaceutical are pictured in Montreal.
report on business
Ex-Valeant executive sentenced to prison for fraud
Former Valeant executive Gary Tanner exits the Manhattan Federal Court in New York on Feb. 23, 2017.
rob magazine
Valeant CEO Joseph Papa on why that toxic name — and legacy — has to go
Joseph Papa, chairman and CEO of Valeant Pharmaceuticals.